Short answer
BridgeBio Oncology Therapeutics Inc (BBOT) filed an 8-K current report with the SEC on September 8, 2026 reporting Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1), Item EX-99.2 (Exhibit EX-99.2). September 8, 2026 press release highlights new BBO-8520 data and strategic focus on 2L+ NSCLC combinations.
BridgeBio Oncology Therapeutics Inc 8-K event analysis
AI summary of each reported item and its exhibits
Item 8.01 · Other Events
- September 8, 2026 press release highlights new BBO-8520 data and strategic focus on 2L+ NSCLC combinations
- Pipeline emphasis includes BBO-11818 and BBO-10203 combinations in KRAS-mutant cancers
- Updated corporate presentation reflects recent corporate developments and provides additional investor context
Item EX-99.1 · Exhibit EX-99.1
- BBO-8520 plus pembrolizumab produced 75% ORR at 500 mg QD in 2L+ NSCLC after prior KRAS G12C inhibitor treatment
- BBO-8520 monotherapy delivered 63% ORR and 100% DCR in 41 previously untreated 2L+ NSCLC patients
- No grade 3 liver enzyme elevations reported for BBO-8520 monotherapy, supporting continued combination development
- BBOT prioritizing BBO-8520 combination and BBO-11818/BBO-10203 combinations across KRAS-mutant cancers
- $344.1M liquidity as of June 30, 2026, projected to fund operations into 2028; key data readouts extend through mid-2027
Item EX-99.2 · Exhibit EX-99.2
- BBOT prioritizing BBO-8520 plus pembrolizumab in post-G12C NSCLC, while deprioritizing 1L NSCLC development and further BBO-8520 investment there
- BBO-8520 combination delivered 75% ORR at 500 mg QD and 53% across doses in 17 G12C inhibitor experienced patients
- BBO-11818 and BBO-10203 advancing in KRAS-mutant cancers, with CRC and PDAC combination cohorts enrolling
- BBO-11818 and BBO-10203 data catalysts planned for Q4 2026, increasing near-term clinical readout significance
- $344M cash at Q2 2026 supports projected operations into 2028, reducing near-term financing risk
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other BridgeBio Oncology Therapeutics Inc 8-K filings
Get the next BBOT 8-K as it lands
Follow BBOT for push alerts, or ask the research agent what this filing means.